Stock Price Quote

CIPLA LTD.

NSE : CIPLABSE : 500087ISIN CODE : INE059A01026Industry : Pharmaceuticals & DrugsHouse : Cipla
BSE1488.657.1 (+0.48 %)
PREV CLOSE ( ) 1481.55
OPEN PRICE ( ) 1485.00
BID PRICE (QTY) 1484.50 (58)
OFFER PRICE (QTY) 1489.20 (20)
VOLUME 193550
TODAY'S LOW / HIGH ( )1463.75 1504.65
52 WK LOW / HIGH ( )919.75 1519
NSE1489.156.85 (+0.46 %)
PREV CLOSE( ) 1482.30
OPEN PRICE ( ) 1482.00
BID PRICE (QTY) 1489.15 (2012)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 4389470
TODAY'S LOW / HIGH( ) 1462.70 1504.55
52 WK LOW / HIGH ( )919.5 1519
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 17-08 1935
Management Info
Y K Hamied - Chairman Umang Vohra - Managing Director
Registered Office

Address Cipla House, Peninsula Business Park,Ganpatrao Kadam Marg,Lower Parel,
Mumbai,
Maharashtra-400013

Phone 022-24826000

Email contactus@cipla.com

Website www.cipla.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, Luxembourg, MCX

NEWS

22May Cipla gets USFDA’s final nod for Lanre
Cipla and its wholly owned subsidiary Cipla USA Inc have received the fi..
22May Cipla rises on getting USFDA’s final n
Cipla is currently trading at Rs. 1457.80, up by 14.60 points or 1.01% f..
22May Cipla informs about disclosure
In compliance with the provisions of Regulation 30 of the Securities and..
16May Cipla inks pact to make additional inv
Cipla has signed definitive agreements for further investment of up to R..
15May Exide Industries, Infosys and Jindal S
Exide Industries has invested Rs 74.99 crore by way of subscription in t..

Financials

in Millions
QTR Mar 24 ANNUAL 24
Net Profit1038440772.5
Gross Profit 12242.4 49469.7
Operating Profit 1366555548.1
Net Sales 40366.6165743.4

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Alkem Laboratories (BSE)
peergroup  5460.90 (2.86%)
M.Cap ( in Cr)65293.25
Glaxosmithkline Phar (BSE)
peergroup  2474.50 (4.09%)
M.Cap ( in Cr)41919.52
Gland Pharma (BSE)
peergroup  1880.90 (4.76%)
M.Cap ( in Cr)30980.40
Coral Laboratories (BSE)
peergroup  451.20 (20.00%)
M.Cap ( in Cr)161.20
Pfizer (BSE)
peergroup  4567.85 (1.64%)
M.Cap ( in Cr)20896.88

Shareholding Pattern

FI/BANKS/INSURANCE 5.49%
PROMOTERS 33.47%
MUTUAL FUNDS/UTI 16.83%
NON-INSTITUTION 16.36%
GOVERNMENT 0%
FII 0%

About Cipla Ltd.

Cipla Ltd. was incorporated in the year 1935. Its today's share price is 1488.65. Its current market capitalisation stands at Rs 120200.41 Cr. In the latest quarter, company has reported Gross Sales of Rs. 165035.7 Cr and Total Income of Rs.162551.7 Cr. The company's management includes Rajendra Chopra, Mandar Purushottam Vaidya, Robert Stewart, PR Ramesh, Punita Lal, Ashok Sinha, Adil Zainulbhai, S Radhakrishnan, Umang Vohra, Samina Hamied, MK Hamied, Y K Hamied.

It is listed on the BSE with a BSE Code of 500087 , NSE with an NSE Symbol of CIPLA and ISIN of INE059A01026. It's Registered office is at Cipla House, Peninsula Business Park,Ganpatrao Kadam Marg,Lower ParelMumbai-400013, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are RGN Price & Co, RS Bharucha & Co, V Sankar Aiyar & Co, Walker Chandiok & Co LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.